Clinical Utility of Soluble CD163 and its Diagnostic and Prognostic Value
in a Variety of Neurological Disorders

Tajbakhsh, Amir; Savardashtaki, Amir; Rezaee, Maryam; Foroutan, Fatemeh; Etemad, Leila; Razban, Vahid

doi:10.2174/1389557523666230106120302

Cited by 3 publications

(5 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are drugs for other diseases that regulate sCD163 production. 16 It would also be of interest to explore the association between sCD163 and the progression of DR in patients with type 2 diabetes.…”

Section: Discussionmentioning

confidence: 99%

“… 15 The enzymes ADAM17/TACE and ADAM10 contribute to increased shedding of sCD163 from macrophages. 16 …”

Section: Introductionmentioning

confidence: 99%

“…15 The enzymes ADAM17/TACE and ADAM10 contribute to increased shedding of sCD163 from macrophages. 16 Increased levels of sCD163 have been demonstrated in the vitreous in patients WHAT IS ALREADY KNOWN ON THIS TOPIC ⇒ Soluble CD163 concentration in the vitreous is increased in patients with proliferative diabetic retinopathy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Soluble CD163 and glycated haemoglobin were independently associated with the progression of diabetic retinopathy in adult patients with type 1 diabetes

et al. 2023

View full text Add to dashboard Cite

ObjectiveHigh vitreous levels of soluble (s)CD163 have been demonstrated in severe diabetic retinopathy (DR). The aim of this study was to explore the predictive values of plasma sCD163 and glycated haemoglobin (HbA1c) for DR progression in adults with type 1 diabetes.Methods and analysesThe study design was prospective. Fundus photography performed in 2009 and at follow-up (≤12 years later) were compared after being categorised according to the International Clinical Diabetic Retinopathy Disease Severity Scale. ‘DR progression at least one level’ was calculated. In 2009, data collection (sex, age, diabetes duration, metabolic variables, serum creatinine, macroalbuminuria and lifestyle factors) and biochemical analyses were performed. Plasma sCD163 and HbA1c were divided into quartiles. Logistic regression analyses were performed.ResultsThe prevalence of DR in 2009 versus at follow-up in 270 participants (57% male) were: no apparent 28% vs 18%; mild 20% vs 13%; moderate 24% vs 26%; severe 11% vs 13%; and proliferative DR 17% vs 30% (p<0.001). DR progression occurred in 101 (45%) patients. HbA1c ≥54 mmol/mol (≥7.1%) (>1st quartile) (adjusted odds ratio (AOR) 3.8, p<0.001) and sCD163 ≥343 ng/mL (>1st quartile) (AOR 2.6, p=0.004) were independently associated with DR progression. The associations with DR progression increased significantly from the first to the fourth quartile for HbA1c (AORs: 1; 2.5; 3.6; 7.4), but not for sCD163 (AORs: 1; 2.9; 2.4; 2.4).ConclusionPlasma sCD163 may constitute a valuable biomarker for DR progression in addition to and independent of the well-established biomarker HbA1c.

show abstract

Section: Discussionmentioning

confidence: 99%

“… 15 The enzymes ADAM17/TACE and ADAM10 contribute to increased shedding of sCD163 from macrophages. 16 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble CD163 and glycated haemoglobin were independently associated with the progression of diabetic retinopathy in adult patients with type 1 diabetes

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Previous studies have demonstrated the association of Semaphorin-7A (Sema7A) with various diseases such as multiple sclerosis lesions [ 16 ], rheumatoid arthritis [ 17 ], acute aortic dissection [ 18 ], etc. It has been reported that CD163 may be a potential biomarker for infectious diseases [ 19 ], immune diseases [ 20 ], tumors [ 21 ] and Neurological Disorders [ 22 ]. Sema7A [ 23 ] and CD163 [ 24 ] have elevated expression in response to inflammation, and they both play a role in atherogenesis.…”

Section: Introductionmentioning

confidence: 99%

Differential expression of Semaphorin-7A /CD163-positive macrophages in large artery and cardiogenic stroke

Jiang,

Sun,

et al. 2024

BMC Neurol

View full text Add to dashboard Cite

Background Identification of the causes of stroke of undetermined etiology, specifically cardioembolism (CE) and non-CE causes, can inform treatment planning and prognosis prediction. The objective of this study was to analyze the disparities in thrombus composition, particularly Semaphorin-7A (Sema7A) and CD163, between patients diagnosed with large-artery atherosclerosis (LAA) and those with CE, and to investigate their potential association with prognosis. Methods Thrombi were collected from patients who underwent mechanical thrombectomy at two hospitals. The patients were categorized into two groups: LAA and CE. We compared the levels of Sema7A and CD163 between these groups and analyzed their relationships with stroke severity, hemorrhagic transformation and prognosis. Results The study involved a total of 67 patients. Sema7A expression was found to be significantly higher in the CE group compared to LAA (p < 0.001). Conversely, no statistically significant differences were observed for CD163 between the groups. The presence of Sema7A/CD163 did not show any associations with stroke severity or hemorrhagic transformation (all p > 0.05). However, both Sema7A (OR, 2.017; 95% CI, 1.301–3.518; p = 0.005) and CD163 (OR, 2.283; 95% CI, 1.252–5.724; p = 0.03) were associated with the poor prognosis for stroke, after adjusting for stroke severity. Conclusion This study highlights that CE thrombi exhibited higher levels of Sema7A expression compared to LAA thrombi. Moreover, we found a positive correlation between Sema7A/CD163 levels and the poor prognosis of patients with acute ischemic stroke.

show abstract

“…Also, neurological diseases are associated with inflammatory conditions and several differences in the levels of biomarkers in neurological diseases compared to normal conditions were reported [ 33 ]. Among these biomarkers, soluble CD163 (sCD163) levels increase in both CSF and plasma samples, related to the activation of macrophage/microglia and inflammation levels in neurological diseases, supporting its role also as a cognitive impairment biomarker [ 34 , 35 , 36 , 37 ]. sCD163 is a soluble form of CD163, a receptor for haptoglobin–hemoglobin complexes and a monocyte/macrophage-specific membrane protein.…”

Section: Introductionmentioning

confidence: 99%

Biomarkers of Neurological Damage: From Acute Stage to Post-Acute Sequelae of COVID-19

Zingaropoli,

Pasculli,

Barbato

et al. 2023

Cells

View full text Add to dashboard Cite

Neurological symptoms (NS) in COVID-19 are related to both acute stage and long-COVID. We explored levels of brain injury biomarkers (NfL and GFAP) and myeloid activation marker (sCD163) and their implications on the CNS. Materials and Methods: In hospitalized COVID-19 patients plasma samples were collected at two time points: on hospital admission (baseline) and three months after hospital discharge (Tpost). Patients were stratified according to COVID-19 severity based on acute respiratory distress syndrome (ARDS) onset (severe and non-severe groups). A further stratification according to the presence of NS (with and without groups) at baseline (requiring a puncture lumbar for diagnostic purposes) and according to NS self-referred at Tpost was performed. Finally, cerebrospinal fluid (CSF) samples were collected from patients with NS present at baseline. Results: We enrolled 144 COVID-19 patients (62 female/82 male; median age [interquartile range, IQR]): 64 [55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77]) and 53 heathy donors (HD, 30 female/23 male; median age [IQR]: 64 [59,60,61,62,63,64,65,66,67,68,69]). At baseline, higher plasma levels of NfL, GFAP and sCD163 in COVID-19 patients compared to HD were observed (p < 0.0001, p < 0.0001 and p < 0.0001, respectively), especially in those with severe COVID-19 (p < 0.0001, p < 0.0001 and p < 0.0001, respectively). Patients with NS showed higher plasma levels of NfL, GFAP and sCD163 compared to those without (p = 0.0023, p < 0.0001 and 0.0370, respectively). At baseline, in COVID-19 patients with NS, positive correlations between CSF levels of sCD163 and CSF levels of NfL (ρ = 0.7536, p = 0.0017) and GFAP were observed (ρ = 0.7036, p = 0.0045). At Tpost, the longitudinal evaluation performed on 77 COVID-19 patients showed a significant reduction in plasma levels of NfL, GFAP and sCD163 compared to baseline (p < 0.0001, p < 0.0001 and p = 0.0413, respectively). Finally, at Tpost, in the severe group, higher plasma levels of sCD163 in patients with NS compared to those without were reported (p < 0.0001). Conclusions: High plasma levels of NfL, GFAP and sCD163 could be due to a proinflammatory systemic and brain response involving microglial activation and subsequent CNS damage. Our data highlight the association between myeloid activation and CNS perturbations.

show abstract

Clinical Utility of Soluble CD163 and its Diagnostic and Prognostic Value in a Variety of Neurological Disorders

Cited by 3 publications

References 105 publications

Soluble CD163 and glycated haemoglobin were independently associated with the progression of diabetic retinopathy in adult patients with type 1 diabetes

Soluble CD163 and glycated haemoglobin were independently associated with the progression of diabetic retinopathy in adult patients with type 1 diabetes

Differential expression of Semaphorin-7A /CD163-positive macrophages in large artery and cardiogenic stroke

Biomarkers of Neurological Damage: From Acute Stage to Post-Acute Sequelae of COVID-19

Contact Info

Product

Resources

About